Hada Celicia Macher

Dr. Hada Celicia Macher

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 December 2021 in Cancers
Verified
Journal Article
Open access
PDF file
JPJavier Padillo
Javier Padillo
GSGonzalo Suarez
Gonzalo Suarez
SPSheila Pereira
Sheila Pereira
FCFrancisco José Calero Castro
Francisco José Calero Castro
JTJose Tinoco
Jose Tinoco
MSMaría Jose Serrano
María Jose Serrano
Background. Effective biomarkers are needed to enable personalized medicine for pancreatic cancer patients. This study analyzes the prognostic value, in early pancreatic cancer, of single circulating tumor cell (CTC) and CTC clusters from the central venous catheter (CVC) and portal blood (PV). Methods. In total, 7 mL of PV and CVC blood from 35 patients with early pancreatic cancer were analyzed. CTC were isolated using a positive immunomagnetic selection. The detection and identification of CTC were performed by immunocytochemistry (ICC) and were analyzed by Epi-fluorescence and confocal microscopy. Results. CTC and the clusters were detected both in PV and CVC. In both samples, the CTC number per cluster was higher in patients with grade three or poorly differentiated tumors (G3) than in patients with well (G1) or moderately (G2) differentiated. Patients with fewer than 185 CTC in PV exhibited a longer OS than patients with more than 185 CTC (24.5 vs. 10.0 months; p = 0.018). Similarly, patients with fewer than 15 clusters in PV showed a longer OS than patients with more than 15 clusters (19 vs. 10 months; p = 0.004). These significant correlations were not observed in CVC analyses. Conclusions. CTC presence in PV could be an important prognostic factor to predict poor prognosis in early pancreatic cancer. In addition, the number of clustered-CTC correlate to a tumor negative differentiation degree and, therefore, could be used as a diagnostic biomarker for pancreatic cancer.

1 February 2021 in Clinical Genetics
Verified
Journal Article
Closed access
PDF file
RDRocío Delarosa‐Rodríguez
Rocío Delarosa‐Rodríguez
JSJosé D. Santotoribio
José D. Santotoribio
HPHernández‐Arévalo Paula
Hernández‐Arévalo Paula
AGAntonio González‐Meneses
Antonio González‐Meneses
SGSalvador García‐Morillo
Salvador García‐Morillo
HMHada Celicia Macher
Hada Celicia Macher

21 May 2021 in Orphanet Journal of Rare Diseases
Verified
Journal Article
Open access
PDF file
PHPaula Hernández-Arévalo
Paula Hernández-Arévalo
JSJosé D. Santotoribio
José D. Santotoribio
RDRocío Delarosa-Rodríguez
Rocío Delarosa-Rodríguez
AGAntonio González-Meneses
Antonio González-Meneses
SGSalvador García-Morillo
Salvador García-Morillo
HMHada Celicia Macher
Hada Celicia Macher
Background: Pompe disease (PD) is an autosomal recessive metabolic disorder caused by pathogenic variants in the acid α-glucosidase gene (GAA) that produces defects in the lysosomal acid α-1,4-glucosidase. We aimed to identify genetic variations and clinical features in Spanish subjects to establish genotype–phenotype correlation. Methods: A total of 2637 samples of patients who showed symptoms or susceptible signs of PD were enrolled in this observational study. Enzymatic activity was detected by fluorometric techniques and the genetic study was carried out using Next-Generation Sequencing. Results: Fourteen different variants from 17 diagnosed patients were identified, seven males and nine females with LOPD (mean age 36.07, SD 20.57, range 7–64) and a 2-day-old boy with IOPD, four genetic variants had not been described in the literature previously, including a homozygous variant. In all of them α-glucosidase activity was decreased. Muscle weakness, respiratory distress, exercise intolerance, hypotonia, dysphagia and myalgia were commonly observed in patients. Conclusions: This study report four new genetic variants that contribute to the pathogenic variants spectrum of the GAA gene. We confirm that patients in Spain have a characteristic profile of a European population, with c.-32-13T>G being the most prevalent variant. Furthermore, it was confirmed that the c.236_246delCCACACAGTGC pathogenic variant in homozygosity is associated with early disease and a worse prognosis.

18 October 2016
Verified
Book Chapter
Closed access
PDF file
MFMarta Ferro
Marta Ferro
HMHada Celicia Macher
Hada Celicia Macher
PNPilar Noguerol
Pilar Noguerol
PJPilar Jimenez-Arriscado
Pilar Jimenez-Arriscado
PMPatrocinio Molinero
Patrocinio Molinero
ARAmalia Rubio
Amalia Rubio

1 October 2018 in Medicine
Verified
Journal Article
Open access
MLMyriam Ley-Martos
Myriam Ley-Martos
JGJuan M. Guerrero
Juan M. Guerrero
MLMarta Lucas-Javato
Marta Lucas-Javato
CRCristina Remón-García
Cristina Remón-García
JGJ. Raúl García-Lozano
J. Raúl García-Lozano
HMHada Celicia Macher
Hada Celicia Macher
Rationale: Mucopolysaccharidosis type VI (MPS VI) or Maroteaux-Lamy syndrome is produced by the deficiency of the enzyme arylsulfatase B, responsible for the hydrolysis of N-acetyl-D-galactosamine, chondroitin sulfate, and dermatan sulfate. Patient concerns: A 3-year-old male with Moroccan origins is the index case. He had healthy consanguineous parents and 4 healthy brothers and sisters. The patient showed a wide spectrum of symptoms including skeletal dysplasia and short stature with elevated glycosaminoglycans (GAGs) in urine. Diagnoses, interventions, and outcomes: GAGs were quantified by spectrometry method with 1,9-dimethylen blue in 24-hour urine samples. The qualitative analysis of urine GAGs was obtained by thin-layer chromatography to determine the predominant presence of dermatan sulfate. The activities of both arylsulfatase B and beta-galactosidase as well as genetic studies were performed in dried blood spots. The genetic study was performed with deoxyribonucleic acid by massive sequencing a of lisosomal storage diseases. Results showed a new mutation c.263A > C with the severe phenotype in homozygous in the patient. The familiar study of ARSB and GLB1 genes presented some asymptomatic SNPs but with a discrete decrease in the activity of arylsulfatase B and beta-galactosidase. After an early detection by pediatricians, and both enzymatic and genetic confirmation, the patient had a good response to substitutive enzymatic treatment with galsulfase. Lessons: Mucoplysaccharidosis type VI is an autosomal recessive rare disease characterized by a lysosomal storage disorder. Although a number of mutations have been already associated to the disease, we have found a new mutation located in the arylsulfatase B enzyme gene. We have described that this mutation is the ultimate cause of a severe presentation of the disease.

23 December 2020 in Research Square
Verified
Preprint
Open access
PDF file
PHPaula Hernandez-Arevalo
Paula Hernandez-Arevalo
JSJose D. Santotoribio
Jose D. Santotoribio
RDRocio Delarosa-Rodriguez
Rocio Delarosa-Rodriguez
AGAntonio Gonzalez-Meneses
Antonio Gonzalez-Meneses
SGSalvador Garcia-Morillo
Salvador Garcia-Morillo
HMHada Celicia Macher
Hada Celicia Macher
Background: Pompe disease (PD) is an autosomal recessive metabolic disorder caused by mutations in the acid α-glucosidase gene (GAA) that produces defects in the lysosomal acid α-1,4-glucosidase. We aimed to identify genetic variations and clinical features in Spanish subjects to establish genotype-phenotype correlation.Methods: A total of 2709 subjects who showed symptoms or susceptible signs of PD were enrolled in this observational study. Enzymatic activity was detected by fluorometric techniques and the genetic study was carried out using Next-Generation Sequencing.Results: Fourteen different variants from seventeen patients were identified, four of whom had not been described in the literature previously, including a homozygous variant. In all of them α-glucosidase activity was decreased. Muscle weakness, respiratory distress, exercise intolerance, hypotonia, dysphagia and myalgia were commonly observed in patients. Conclusions: This study report four new mutations that contribute to the mutation spectrum of the GAA gene. We confirm that patients in Spain have a characteristic profile of a European population, with c.-32-13T> G being the most prevalent variant. Furthermore, it was confirmed that the c.236_246delCCACACAGTGC mutation in homozygosis is associated with early disease and a worse prognosis.